Scope of US Patent 12,246,006 (Clotrimazole BFS single-dose liquids) and US patent landscape: claims coverage, likely infringement surfaces, and generic entry risks
US Patent 12,246,006 is directed to a sterile, single-dose blow-fill-seal (BFS) container filled with a clotrimazole solution. The core claim spine is: clotrimazole is the only active ingredient, formulated with polyethylene glycol (PEG) as solubilizing agent, at very low water content (≤4 wt%, preferably ≤3 wt%), in a small-volume BFS unit (0.05 to 8 mL), with specified PEG grades and thermoplastic polymer container materials, plus dependent claims on secondary packaging oxygen barrier.
The patent’s practical commercial threat is product form (small-dose BFS sterile liquid clotrimazole) and product chemistry (PEG-solubilized clotrimazole solution with controlled water). It is less about the therapeutic indication and more about composition + container + water content + solubilizer + packaging environment.
What patents protect clotrimazole sterile single-dose blow-fill-seal BFS solutions in the US?
Immediate scope: the independent claim (claim 1)
Claim 1 sets a tight combination of limitations that collectively define the invention:
- Single-dose packaging unit
- BFS container
- Sterile pharmaceutical or veterinary liquid composition
- Composition is a solution
- Clotrimazole at a therapeutically effective amount
- Clotrimazole is the single active ingredient
- One or more acceptable excipients/carriers are allowed
- A solubilizing agent is polyethylene glycol (PEG)
- Container volume 0.05 to 8 mL
- Water content ≤4 wt% (relative to total composition weight)
This combination is narrower than a general “clotrimazole liquid formulation.” It is also narrower than “clotrimazole + PEG” alone because it additionally requires BFS single-dose format and tight water content constraints.
Dependent claim coverage that expands the claim estate
The dependent claims broaden within the same chemistry and packaging family:
- Dose/concentration range (claim 2): clotrimazole 0.1 to 5% by weight
- PEG selection (claim 3): PEG 200, 300, 400, 600 or mixtures
- Container polymer (claim 4): thermoplastic polymer selected from PE/LDPE/HDPE/PP
- Sterility (claim 5): explicit sterile requirement
- Water constraint tightened (claim 6): ≤3 wt%
- Secondary packaging (claims 7–12): oxygen and barrier environment:
- oxygen inside secondary packaging ≤10% vol, also ≤5% or ≤2% vol
- secondary packaging can be aluminium foil complex overwrap pouch
- inert gas option or gas absent option
- Specific embodiments (claims 13–17):
- Example narrowing: LDPE container polymer (claims 13, 17)
- Combine LDPE + PEG + tighter water constraints (claims 16–17)
Net effect: the patent is positioned to capture both (a) primary packaging infringement (BFS unit plus polymer plus water content) and (b) secondary packaging/environment infringement (oxygen level in overwrap pouch).
How broad are the claims for US 12,246,006 and what are the key claim boundaries?
The invention is combination-claim constrained
Because claim 1 is conjunctive (BFS + sterile solution + clotrimazole only active + PEG solubilizer + specified water content + BFS volume), a design-around must break at least one material limitation. Likely boundaries:
- Active ingredient restriction: clotrimazole must be the single active ingredient.
- Adding a second antifungal active, keratolytic, steroid, anesthetic, or antiseptic active can avoid this element.
- Solubilizer restriction: PEG must be the solubilizing agent.
- Switching solubilizer to e.g., propylene glycol, polysorbate, cyclodextrins, or other solvents may avoid this limitation if it is not “PEG as solubilizing agent.”
- Water content restriction: ≤4 wt% and optionally ≤3 wt%.
- Increasing water content above the thresholds, or using a different “water management” strategy (e.g., cosolvents that reduce free water without increasing total water) matters, but infringement turns on “water content” measurement.
- BFS and container format: “single-dose packaging unit” and “BFS container.”
- Using a different sterile fill method (e.g., sterile vial + syringe, blister, prefilled syringe with different forming method) risks non-infringement of the BFS limitation.
- BFS volume range: 0.05 to 8 mL.
- Moving outside the range (larger units or smaller micro-volume below 0.05 mL) can be a boundary.
- PEG grade list in dependents: PEG 200/300/400/600 are explicit in dependent claims. Even if claim 1 covers “PEG” generally, dependent claims narrow to specific grades.
What the patent does NOT claim explicitly
- Indication (dermatology vs veterinary vs device adjunct) is not in claim language you provided.
- Mechanism of action is not the novelty anchor; formulation and packaging are.
- Dosage regimen is not claimed in the provided claim set.
Which claim elements are most likely to drive infringement in the US?
Most infringement-sensitive elements
- BFS primary packaging (single-dose BFS)
- Water content threshold (≤4 wt%, and potentially ≤3 wt%)
- PEG solubilizer where PEG is the solubilizing agent
- Clotrimazole is the only active ingredient
- Volume 0.05 to 8 mL
Secondary packaging oxygen claims (claims 8–12)
These create a second infringement surface if the product uses an overwrap/secondary package with controlled oxygen:
- If oxygen inside the secondary package is ≤10% vol, then claim 8 is implicated.
- If ≤5% vol or ≤2% vol, then claims 9 are implicated.
- Barrier format is supported by claim 10: aluminium foil complex overwrap pouch.
- Gas handling options in claims 11–12 (inert gas present vs gas absent) create multiple embodiments.
This matters if a generic candidate changes only primary formulation but keeps the same secondary package architecture.
What formulations are covered: clotrimazole + PEG solution with low water in BFS containers?
Composition structure implied by claim 1
- Active: clotrimazole (single active ingredient)
- Solubilizer: PEG (must be present as solubilizing agent)
- Excipients/carriers: allowed but must not introduce a second active ingredient
- State: sterile solution
- Water content: ≤4 wt% (or ≤3 wt% in dependents)
PEG grades covered
- Claim 3: PEG 200/300/400/600 or mixtures
- Dependents (13–17) specify LDPE container polymer but keep PEG/water constraints in-range.
Container materials covered
- Claim 4: polymer selected from PE, LDPE, HDPE, PP
- Dependents provide an embodiment with LDPE.
BFS unit volume range
Implication: a candidate product outside those container materials or volume range, even if chemically similar, is likely outside claim 1.
When does US 12,246,006 lose exclusivity and what patent term constraints apply?
No expiration date, filing date, or patent term data was provided for US 12,246,006 in the prompt. Without the application/priority data and patent grant details, a precise exclusivity or expiration timeline cannot be produced.
Result: no actionable expiration/exclusivity schedule can be stated from the provided information.
What generic entry risks exist for clotrimazole BFS liquid products under US 12,246,006?
High-risk “copy-the-format” strategy
A generic or authorized alternative that matches:
- BFS single-dose packaging,
- solution formulation with PEG as solubilizer,
- low water content (≤4 wt%),
- clotrimazole as the only active,
- and volume 0.05–8 mL,
is at elevated risk for infringement.
Design-around pathways (what to change to break claim elements)
Because claim 1 is combination-limited, generic entry risk declines when a candidate breaks at least one required element:
- Change active ingredient set
- Add a second active to avoid “clotrimazole is the single active ingredient” or remove clotrimazole as the only active.
- Change solubilizing system
- Use a different solubilizer system not characterized as PEG “the solubilizing agent.”
- Adjust water content above thresholds
- Increase water content above ≤4 wt% (or above ≤3 wt% for the narrower dependent claim).
- Change primary container platform
- Avoid BFS single-dose packaging units, or change the packaging architecture so it is not a BFS container.
- Move outside the volume range
- Use larger-than-8 mL or smaller-than-0.05 mL unit volumes.
- Secondary packaging oxygen strategy
- If the candidate uses a secondary package with oxygen above the claimed thresholds, claims 8–9 may be avoided even if primary packaging/formulation is similar.
The core takeaway: the patent is most vulnerable to “one-limitation breaks,” not incremental tweaks.
How strong is the patent estate for US 12,246,006 based on claim structure?
Strength indicators from claim drafting
- Narrow combination claim: reduces the probability that unrelated clotrimazole liquids infringe.
- Multiple dependent claims on PEG grades, polymer materials, and water tightening: supports consistent infringement theories across multiple embodiments.
- Secondary packaging oxygen claims: adds manufacturing and packaging process leverage.
Strength limitations
- If competitors can change solubilizer, water content, or primary container format, the independent claim may be avoided.
- Dependent claims narrow additional constraints; they increase coverage where a candidate keeps the same low-water PEG BFS approach and uses controlled oxygen overwrap.
How does US 12,246,006 compare with typical clotrimazole formulation patents?
Typical formulation IP for imidazole antifungals tends to cover:
- drug-excipient combinations,
- specific solubilizers,
- viscosity/penetration modifiers,
- and dosage forms.
This patent adds explicit industrial packaging constraints:
- BFS single-dose unit,
- very low water content,
- PEG solubilizer as the specified solubilizing agent,
- and oxygen-controlled secondary overwrap.
Comparative positioning: it sits at the intersection of formulation and packaging engineering. That makes it harder to invalidate by arguing only generic “formulation obviousness,” but it also makes it easier for a competitor to design around by changing manufacturing and packaging format.
What patent litigation affects clotrimazole BFS formulations in the US?
No litigation docket, parties, asserted patents, or settlements were provided for US 12,246,006 in the prompt. Without those data, the litigation landscape cannot be accurately mapped.
Result: no litigation effects can be stated from the provided information.
What is the Orange Book status of US 12,246,006 and which companies are challenging it?
The prompt does not include the drug product name tied to this patent, FDA NDA/ANDA/BLA identifiers, or Orange Book listings. Without those identifiers, the Orange Book status and any Paragraph IV challenges cannot be determined.
Result: no Orange Book and challenger mapping can be produced.
Key Takeaways
- US 12,246,006 claims a sterile clotrimazole solution in a BFS single-dose container with PEG as solubilizing agent and controlled low water (≤4 wt%, ≤3 wt% in dependents).
- The independent claim is narrow and combination-constrained: BFS format + PEG solubilizer + clotrimazole as the sole active + water threshold + 0.05–8 mL volume.
- Dependent claims add PEG grade options, thermoplastic polymer materials, and secondary packaging oxygen barrier limits (≤10%, ≤5%, ≤2% vol oxygen), including aluminium foil complex overwrap pouch with inert gas or gas absence.
- Generic entry risk is highest for candidates that match both primary BFS low-water PEG chemistry and secondary oxygen-controlled packaging; risk drops when a candidate breaks a required limitation (solubilizer, water content, active ingredient set, BFS platform, or volume).
FAQs
- If a clotrimazole liquid uses PEG but has water content above 4 wt%, does it avoid claim 1?
- Does adding a second active ingredient (e.g., another antifungal) bypass the “single active ingredient” limitation?
- How do oxygen specifications in the secondary packaging affect infringement when primary formulation is unchanged?
- Can a competitor avoid the BFS limitation by using a different sterile fill-and-finish platform (e.g., vials or blister)?
- Do the dependent claims’ PEG 200/300/400/600 lists limit scope beyond claim 1’s broader “polyethylene glycol” language?
References
- User-provided claim text for US Patent 12,246,006 (claims 1–17).
